Biosimilars
31 results
Applied filters
The licence and supporting evidence for denosumab 60mg biosimilars
24 April 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 April 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.
The licence and supporting evidence for tocilizumab biosimilar
6 March 2026Two licensed tocilizumab biosimilars are available: Tyenne and Avtozma. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use tocilizumab biosimilar
6 March 2026Two tocilizumab biosimilars are now available. We offer general information and implementation advice.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use denosumab 60mg biosimilar
16 January 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
16 January 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.